Results 161 to 170 of about 2,751,693 (208)
Expression of Concern: Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance. [PDF]
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
Daniela Cilloni +2 more
exaly +4 more sources
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
Daniela Cilloni +2 more
exaly +4 more sources
hOCT 1 and Resistance to Imatinib
Blood, 2005![ Figure 1. ][1] Figure 1. The pre-imatinib hOCT1 expression level in nonresponders (NRs) and responders (Rs). Imatinib is a substrate for the adenosine triphosphate–binding cassette (ABC) transporters ABCB1 [1][2]-[3][3] and ABCG2 [4][4],[5][5]; however, it is unclear ...
Brian Druker +2 more
exaly +3 more sources
Decrease of Resistance to Imatinib in Leukaemia
Lancet, The, 2002Carlo Gambacorti-Passerini
exaly +3 more sources
Resistance to Imatinib: Mutations and Beyond
Seminars in Hematology, 2010Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the kinase domain of BCR-ABL as a major
Paul, La Rosée, Michael W, Deininger
openaire +2 more sources
Metabolic Characteristics of Imatinib Resistance in Chronic Myeloid Leukaemia Cells
Background and purpose: Early detection of resistance development is crucial for imatinib-based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish metabolic markers of cell resistance to imatinib.
Uwe Christians +2 more
exaly +2 more sources
Imatinib resistance in gastrointestinal stromal tumors
Current Oncology Reports, 2005Conventional chemotherapeutic drugs are ineffective in treatment of gastrointestinal stromal tumors (GISTs). Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients
Lei L, Chen +9 more
openaire +2 more sources
Resistance to Imatinib (Glivec): Update on Clinical Mechanisms
Drug Resistance Updates, 2003Imatinib mesylate, an orally administered 2-phenylaminopyrimidine derivative that inhibits BCR/ABL tyrosine kinase activity, has shown great promise in the treatment of chronic myelogenous leukemia (CML). This small molecule, tyrosine kinase inhibitor, has also been shown to be effective against metastatic gastrointestinal stromal tumors (GISTs ...
Ellen Weisberg, James D Griffin
exaly +3 more sources
Clinical resistance to imatinib: mechanisms and implications
Hematology/Oncology Clinics of North America, 2004Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy. The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within ...
Hochhaus, A., Hughes, T.
openaire +3 more sources
Blood, 2007
Abstract Statins (HMG-CoA reductase inhibitors) are known to show antiproliferative effects and are anticipated as a potential drug in the treatment of malignancies including acute myelogenous leukemia (AML) and multiple myeloma (MM). Using cell proliferation assays, we determined the effects of simvastatin in CML cells.
Bora Oh +4 more
openaire +1 more source
Abstract Statins (HMG-CoA reductase inhibitors) are known to show antiproliferative effects and are anticipated as a potential drug in the treatment of malignancies including acute myelogenous leukemia (AML) and multiple myeloma (MM). Using cell proliferation assays, we determined the effects of simvastatin in CML cells.
Bora Oh +4 more
openaire +1 more source

